#Sweden #Gothenburg #revenue growth #Zinzino #Faun Pharma

Zinzino AB's Preliminary Sales Report for July 2025

Zinzino AB has recently announced its preliminary sales figures for July 2025, revealing a substantial revenue boost of 64% year-on-year. This surge has propelled the company's total revenue to SEK 259.9 million, a significant rise from SEK 158.8 million in the same month of the previous year. The overall financial health of the Zinzino group has also improved, with a notable increase of 55% in total revenues, amounting to SEK 262.1 million, compared to SEK 169.1 million in July 2024.

Key Financial Highlights

The revenue distribution across various regions further highlights Zinzino's growth trajectory:

• - The Nordics: Revenue increased by 12% to SEK 26.1 million.
• - Central Europe: This region saw a remarkable 73% growth, reaching SEK 76.1 million.
• - East Europe: Revenue remained stable with a slight increase of 8% to SEK 31.3 million.
• - South West Europe: A significant growth of 42% resulted in revenue of SEK 47.3 million.
• - The Baltics: Revenue increased by 25%, totaling SEK 10 million.
• - North America: Exceptional growth of 183% brought in SEK 47.2 million.
• - Asia-Pacific: This region showcased staggering growth of 590%, with a revenue of SEK 20 million.
• - Africa: A moderate increase of 36% resulted in SEK 1.9 million.

When looking at the accumulated revenue from January to July 2025, Zinzino recorded a 57% increase, culminating in SEK 1,780.1 million, compared to SEK 1,130.7 million during the same period last year. These figures reflect both an effective growth strategy and robust market demand for Zinzino’s products.

Challenges in External Sales

While the overall performance has been encouraging, Zinzino faced challenges with Faun Pharma's external sales, which fell sharply by 79%, totaling SEK 2.2 million down from SEK 10.3 million. Despite this setback, the overall Zinzino group has managed to keep its revenue growth in a positive light.

Strategic Insights

The staggering growth rates, particularly in North America and the Asia-Pacific region, suggest that Zinzino's expansion strategies may be paying dividends. North America reported a 205% increase when considering year-to-date performance, emphasizing the successful penetration and acceptance of Zinzino’s offerings in this competitive market.

Additionally, the Asia-Pacific region, with its 499% year-to-date increase, hints at vast untapped potential as more consumers seek health and wellness products, further showcasing Zinzino’s appeal.

Conclusion

In conclusion, Zinzino AB's preliminary sales report for July 2025 not only reflects impressive revenue growth but also underscores the company's resilience and ability to adapt amid market fluctuations. Moving forward, stakeholders will be closely observing how Zinzino maneuvers its future strategies, especially in light of the challenges faced by Faun Pharma. As the company continues to innovate and expand, its commitment to boosting consumer health remains steadfast, positioning it well for continued growth in the future.